Bridgewater-based Salix Pharmaceuticals and Kentucky-based US WorldMeds LLC have brought to market the first and only FDA-approved nonopioid medication to temper symptoms of withdrawal caused by the stoppage of opioid-use.
According to the companies, Lucemyra works by reducing the release of norepinephrine, a neurotransmitter, to suppress rushes from the nervous system that produce opioid withdrawal. The drug was developed through a collaboration with, and grant from, the National Institute on Drug Abuse, part of the National Institutes of Health.
“By effectively intervening during withdrawal and helping to control severe, disabling withdrawal symptoms, Lucemyra can help provide a starting point toward recovery,” Salix President Mark McKenna said in a release.
Lucemyra is an oral tablet. The most common side effects are low blood pressure, lightheadedness, slow heart rate, dizziness, sleepiness and dry mouth.
Qualifying patients can receive the prescription drug per a co-pay program associated with the launch offering prices for as low as $25.